Literature DB >> 7609230

Looking through a keyhole at the tobacco industry. The Brown and Williamson documents.

S A Glantz1, D E Barnes, L Bero, P Hanauer, J Slade.   

Abstract

OBJECTIVE: To introduce a series of papers discussing previously undocumented tobacco industry activities regarding strategies to avoid products liability litigation, understand nicotine addiction, and manipulate both internal and external scientific research on the effects of both active and passive smoking. DATA SOURCES: Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. STUDY SELECTION: All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers.
CONCLUSIONS: These documents provide our first look at the inner workings of the tobacco industry during the crucial period in which the scientific case that smoking is addictive and kills smokers solidified. The documents show a sophisticated legal and public relations strategy to avoid liability for the diseases induced by tobacco use. The documents show that lawyers steered scientists away from particular research avenues, which is inconsistent with the company's purported disbelief in the causation and addiction claims; if the company had been genuinely unconvinced by the causation and addiction hypotheses, then it should have had no concern that new research would provide ammunition for the enemy. Quite the contrary, the documents show that B&W and BAT recognized more than 30 years ago that nicotine is addictive and that tobacco smoke is "biologically active" (eg, carcinogenic).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609230

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  26 in total

1.  Universities and tobacco money.

Authors:  J E Cohen
Journal:  BMJ       Date:  2001-07-07

Review 2.  "We are anxious to remain anonymous": the use of third party scientific and medical consultants by the Australian tobacco industry, 1969 to 1979.

Authors:  S Chapman
Journal:  Tob Control       Date:  2003-12       Impact factor: 7.552

3.  Development of a model of the tobacco industry's interference with tobacco control programmes.

Authors:  W M K Trochim; F A Stillman; P I Clark; C L Schmitt
Journal:  Tob Control       Date:  2003-06       Impact factor: 7.552

4.  The most important and influential papers in tobacco control: results of an online poll.

Authors:  S Chapman
Journal:  Tob Control       Date:  2005-10       Impact factor: 7.552

5.  Every document and picture tells a story: using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertising.

Authors:  S J Anderson; T Dewhirst; P M Ling
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

Review 6.  Open doorway to truth: legacy of the Minnesota tobacco trial.

Authors:  Richard D Hurt; Jon O Ebbert; Monique E Muggli; Nikki J Lockhart; Channing R Robertson
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

7.  Goliath and some Davids in the tobacco wars.

Authors:  M Susser
Journal:  Am J Public Health       Date:  1997-10       Impact factor: 9.308

8.  Term limits and the tobacco industry.

Authors:  Dorie E Apollonio; Stanton A Glantz; Lisa A Bero
Journal:  Soc Sci Med       Date:  2013-11-15       Impact factor: 4.634

9.  Tobacco Industry Promotions and Pricing After Tax Increases: An Analysis of Internal Industry Documents.

Authors:  Dorie E Apollonio; Stanton A Glantz
Journal:  Nicotine Tob Res       Date:  2020-05-26       Impact factor: 4.244

10.  Tobacco industry attempts to counter the World Bank report Curbing the Epidemic and obstruct the WHO framework convention on tobacco control.

Authors:  Hadii M Mamudu; Ross Hammond; Stanton Glantz
Journal:  Soc Sci Med       Date:  2008-10-22       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.